Fundraising Fox
Apogee Therapeutics
NASDAQ: APGEFounded 2022 · 340 employees on LinkedIn · 7 known investors
Find your way into Apogee Therapeutics
Sign up to see every warm intro you have to Apogee Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Apogee Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
Founders & leadership
Investors · 7
How we know: Access Biotechnology's portfolio page · Not right? Tell us
How we know: RA Capital's portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · funding news · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BDec 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Founder mafia
3 people who came through Apogee Therapeutics went on to found or lead other companies.
Related companies · 2
Companies working in the same space as Apogee Therapeutics.
In the news
Frequently asked questions
- What does Apogee Therapeutics do?
- Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
- Who are Apogee Therapeutics's investors?
- Apogee Therapeutics's investors include Access Biotechnology, RA Capital, Wellington Management, Blackstone Life Sciences, Perceptive Xontogeny Venture, RTW Investments L.P., Venrock Healthcare Capital Partners.